In the wake of the increase in Current Liabilities in the third quarter 2026, Quick Ratio fell to 1.8 below Sera Prognostics Inc average.

Within Medical Laboratories industry 17 other companies have achieved higher Quick Ratio than Sera Prognostics Inc in third quarter 2026. While Quick Ratio total ranking in the third quarter 2026 has deteriorated compared to the prior quarter from 1152 to 1445.

Explain Quick Ratio?
How much Cash & cash equivalents SERA�s has?
What are SERA�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/SERA/financial-strength

https://api.csimarket.com/api/v1/companies/SERA/fundamentals

https://api.csimarket.com/api/v1/companies/SERA/fundamentals?mode=as_of&as_of=YYYY-MM-DD

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Access this full dataset via API

Free sample Full docs All endpoints

SERA Quick Ratio	(Sep 30 2026) Q3	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3
Y / Y Current Liabilities Change	4.37 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent Change	1.81 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio MRQ	1.8	Subscribe	Subscribe	Subscribe	Subscribe
SERA's Total Ranking	# 1445	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities Change	0.7 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent Change	-5.07 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick Ratio third quarter 2026 Company Ranking
Within:	No.
Medical Laboratories Industry	# 18
Healthcare Sector	# 511
Overall Market	# 1445

Quick Ratio Statistics
High	Average	Low
33.86	7.42	1.56
(Sep 30 2021)		(Dec 31 2020)

Financial Statements
Sera Prognostics Inc 's Current Liabilities	$ 25 Millions	Visit SERA's Balance sheet
Sera Prognostics Inc 's Cash & cash equivalent	$ 44 Millions	Visit SERA's Balance sheet
Source of SERA's Sales		Visit SERA's Sales by Geography

Cumulative Sera Prognostics Inc 's Quick Ratio

SERA's Quick Ratio for the trailling 12 Months

SERA Quick Ratio	(Sep 30 2026) 12 Months	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	1.28 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent TTM Growth	0.7 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio TTM	1.84	Subscribe	Subscribe	Subscribe	Subscribe
Total Ranking TTM	# 2927	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities TTM Growth	1.08 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent TTM Growth	0.45 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick ratio ranking by company, industry and sector >> Back to SERA Financial Strength Comparisons >> Go to Compare SERA Quick Ratio to its Competitors

On the trailing twelve months basis Due to rise in Current Liabilities in the Q3 2026 to $24.53 millions, cumulative Quick Ratio decreased to 1.84 below the Sera Prognostics Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Medical Laboratories industry 36 other companies have achieved higher Quick Ratio than Sera Prognostics Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2026 from 3098 to 4094.

Explain Quick Ratio?
How much Cash & cash equivalents SERA�s has?
What are SERA�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Medical Laboratories Industry	# 37
Healthcare Sector	# 910
Within the Market	#

trailing twelve months Quick Ratio Statistics
High	Average	Low
13.39	3.11	0.16
(Mar 31 2022)		(Sep 30 2024)

Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Medical Laboratories Industry	Quick Ratio	Sep 30 2026 MRQ Cash & cash equivalent	Sep 30 2026 MRQ Current Liabilities
Veracyte Inc	4.40	$ 370.532 Millions	$ 84.209 Millions
Castle Biosciences Inc	4.11	$ 277.665 Millions	$ 67.612 Millions
Fulgent Genetics Inc	4.07	$ 292.739 Millions	$ 71.877 Millions
Omniab Inc	3.81	$ 64.210 Millions	$ 16.853 Millions
Guardant Health Inc	2.75	$ 1,026.848 Millions	$ 373.165 Millions
Incyte Corporation	2.68	$ 3,854.572 Millions	$ 1,437.818 Millions
Exagen Inc	2.14	$ 28.092 Millions	$ 13.100 Millions
Biodesix Inc	1.99	$ 28.409 Millions	$ 14.248 Millions
Caredx Inc	1.80	$ 250.480 Millions	$ 138.975 Millions
Butterfly Network Inc	1.80	$ 122.301 Millions	$ 67.987 Millions
Sera Prognostics Inc	1.80	$ 44.089 Millions	$ 24.527 Millions
Radnet Inc	1.11	$ 797.880 Millions	$ 716.642 Millions
Bioaffinity Technologies Inc	1.01	$ 2.550 Millions	$ 2.533 Millions
Quest Diagnostics Inc	0.49	$ 893.000 Millions	$ 1,834.000 Millions
Medpace Holdings Inc	0.47	$ 705.315 Millions	$ 1,496.097 Millions

Date modified: 2026-11-05T07:00:37+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.